All News

    Navigating Time and Emotions After Testicular Cancer

    February 19th 2025, 6:00pm

    Article

    I often reflect on my emotional changes following a testicular cancer diagnosis and how I learned to manage them and grow.

    Explaining PROs From the TiNivo-2 Study in Advanced Renal Cell Carcinoma

    February 19th 2025, 5:00pm

    Video

    Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.

    What Patients With Cancer Need to Know About Counterfeit Drugs Risk

    February 19th 2025, 4:00pm

    Article

    It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.

    SBRT May Be Superior to Radiofrequency Ablation in Liver Cancer

    February 19th 2025, 2:00pm

    Article

    SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

    UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

    February 18th 2025, 10:00pm

    Article

    Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.

    Cancer Vaccine Elicits Promising Responses in Renal Cell Carcinoma

    February 18th 2025, 8:00pm

    Article

    All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

    The Good and The Bad of Follicular Lymphoma

    February 18th 2025, 6:00pm

    Article

    My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring monitoring and follow-up.

    An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment

    February 18th 2025, 5:00pm

    Video

    Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.

    The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma

    February 18th 2025, 4:00pm

    Article

    The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.

    Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma

    February 18th 2025, 2:00pm

    Article

    Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.